Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
December 21, 2024 at 10:43 AM
Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
www.nature.com
March 19, 2025 at 2:34 AM
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
BREAKING: Osimertinib approved as adjuvant therapy for Stage 1b-3a #EGFR+ #lungcancer after surgery in England! Based on ADAURA trial results showing longer disease-free survival (65.8 vs. 28.1 months).
We worked on this appraisal—it’s a huge step for better access to life-changing care! #LCSM
We worked on this appraisal—it’s a huge step for better access to life-changing care! #LCSM
January 21, 2025 at 9:30 PM
BREAKING: Osimertinib approved as adjuvant therapy for Stage 1b-3a #EGFR+ #lungcancer after surgery in England! Based on ADAURA trial results showing longer disease-free survival (65.8 vs. 28.1 months).
We worked on this appraisal—it’s a huge step for better access to life-changing care! #LCSM
We worked on this appraisal—it’s a huge step for better access to life-changing care! #LCSM
Can MRD detection refine adjuvant osimertinib use in EGFR-mutated NSCLC? A new analysis from ADAURA explores its potential for predicting recurrence.
ascopost.com/news/march-2...
#Oncology #LungCancer
ascopost.com/news/march-2...
#Oncology #LungCancer
March 18, 2025 at 3:18 PM
Can MRD detection refine adjuvant osimertinib use in EGFR-mutated NSCLC? A new analysis from ADAURA explores its potential for predicting recurrence.
ascopost.com/news/march-2...
#Oncology #LungCancer
ascopost.com/news/march-2...
#Oncology #LungCancer
今日は
Black moon のアナエロ
Black moon のウォッシュド
Adaura のDFナチュラルを
家で淹れて飲んでおります
やっぱりどれも抜群に
美味しいねぇ
特にAdauraは格別だなぁ
深夜よりは家で過ごす時間とマッチしてる気がする
煙草とはあんまり合わないけど
やっぱりお外で飲みたいw
Black moon のアナエロ
Black moon のウォッシュド
Adaura のDFナチュラルを
家で淹れて飲んでおります
やっぱりどれも抜群に
美味しいねぇ
特にAdauraは格別だなぁ
深夜よりは家で過ごす時間とマッチしてる気がする
煙草とはあんまり合わないけど
やっぱりお外で飲みたいw
April 13, 2024 at 8:08 AM
今日は
Black moon のアナエロ
Black moon のウォッシュド
Adaura のDFナチュラルを
家で淹れて飲んでおります
やっぱりどれも抜群に
美味しいねぇ
特にAdauraは格別だなぁ
深夜よりは家で過ごす時間とマッチしてる気がする
煙草とはあんまり合わないけど
やっぱりお外で飲みたいw
Black moon のアナエロ
Black moon のウォッシュド
Adaura のDFナチュラルを
家で淹れて飲んでおります
やっぱりどれも抜群に
美味しいねぇ
特にAdauraは格別だなぁ
深夜よりは家で過ごす時間とマッチしてる気がする
煙草とはあんまり合わないけど
やっぱりお外で飲みたいw
Nicola Steele on the radical EGFRm arena - ADAURA-NEOADAURA-LAURA and a cheeky bit of PACIFIC. Targeted treatment sees gains across the board, and given PACIFIC data, LAURA a key trail. Needs desecration criteria to aid reimbursement? #BTOG25
March 3, 2025 at 2:31 PM
Nicola Steele on the radical EGFRm arena - ADAURA-NEOADAURA-LAURA and a cheeky bit of PACIFIC. Targeted treatment sees gains across the board, and given PACIFIC data, LAURA a key trail. Needs desecration criteria to aid reimbursement? #BTOG25
ESPRESSO & MILK BEVERAGE
PANAMA ADAURA GEISHA
美味しい〜。パンチのある酸味。確かに量は飲めない。洋酒みたいなインパクトがある。ミルクもオーツミルクがちょっと入ってるのがちょうどいいバランス。
PANAMA ADAURA GEISHA
美味しい〜。パンチのある酸味。確かに量は飲めない。洋酒みたいなインパクトがある。ミルクもオーツミルクがちょっと入ってるのがちょうどいいバランス。
December 29, 2024 at 6:24 AM
ESPRESSO & MILK BEVERAGE
PANAMA ADAURA GEISHA
美味しい〜。パンチのある酸味。確かに量は飲めない。洋酒みたいなインパクトがある。ミルクもオーツミルクがちょっと入ってるのがちょうどいいバランス。
PANAMA ADAURA GEISHA
美味しい〜。パンチのある酸味。確かに量は飲めない。洋酒みたいなインパクトがある。ミルクもオーツミルクがちょっと入ってるのがちょうどいいバランス。
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Molecular Residual Disease Precedes Disease-Free Survival Events by Months
Major Finding: Molecular residual disease (MRD) preceded death or clinical recurrence in the ADAURA trial by nearly 5 months. Concept: Longitudinal MRD monitoring may stratify risk for patients with E...
aacrjournals.org
June 12, 2025 at 2:41 PM
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Dr jason lambden, cu onc fellow, has a coming out article with me. Nice work dr L dailynews.ascopubs.org/do/adjuvant-...
Adjuvant Osimertinib in EGFR-Mutated NSCLC: The Survival Curves Reveal the Next Set of Questions on How to Optimize Benefits
Osimertinib has significantly improved outcomes for patients with <i>EGFR</i>-mutated non–small cell lung cancer in the adjuvant setting, as demonstrated by the landmark trials ADAURA and LAURA. Howev...
dailynews.ascopubs.org
March 8, 2025 at 1:28 AM
Dr jason lambden, cu onc fellow, has a coming out article with me. Nice work dr L dailynews.ascopubs.org/do/adjuvant-...
3/29 #TumorBoardTuesday
👩🏫Mini tweetorial 2👨🏫
🚨ADAURA Results
💊Adjuvant osimertinib vs placebo
⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001)
⭐️DFS 65.8 mo vs 28.1 mo
🏆Adj osimertinib is now FDA approved/SOC
👩🏫Mini tweetorial 2👨🏫
🚨ADAURA Results
💊Adjuvant osimertinib vs placebo
⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001)
⭐️DFS 65.8 mo vs 28.1 mo
🏆Adj osimertinib is now FDA approved/SOC
December 11, 2024 at 1:11 AM
3/29 #TumorBoardTuesday
👩🏫Mini tweetorial 2👨🏫
🚨ADAURA Results
💊Adjuvant osimertinib vs placebo
⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001)
⭐️DFS 65.8 mo vs 28.1 mo
🏆Adj osimertinib is now FDA approved/SOC
👩🏫Mini tweetorial 2👨🏫
🚨ADAURA Results
💊Adjuvant osimertinib vs placebo
⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001)
⭐️DFS 65.8 mo vs 28.1 mo
🏆Adj osimertinib is now FDA approved/SOC
2/29 #TumorBoardTuesday
👩🏫Mini tweetorial 1👨🏫
✨Phase III Trial ADAURA Trial✨
🔑Key Inclusion Criteria
➡️EGFR Exon 19 del OR L878R mut
➡️ R0 resected Stage IB-IIIA (AJCC 7 ed)
💊Tx: Adjuvant Osimertinib x 3yrs (+/- prior adj chemo)
@DrRoyHerbstYale
@NEJM
👩🏫Mini tweetorial 1👨🏫
✨Phase III Trial ADAURA Trial✨
🔑Key Inclusion Criteria
➡️EGFR Exon 19 del OR L878R mut
➡️ R0 resected Stage IB-IIIA (AJCC 7 ed)
💊Tx: Adjuvant Osimertinib x 3yrs (+/- prior adj chemo)
@DrRoyHerbstYale
@NEJM
December 11, 2024 at 1:08 AM
2/29 #TumorBoardTuesday
👩🏫Mini tweetorial 1👨🏫
✨Phase III Trial ADAURA Trial✨
🔑Key Inclusion Criteria
➡️EGFR Exon 19 del OR L878R mut
➡️ R0 resected Stage IB-IIIA (AJCC 7 ed)
💊Tx: Adjuvant Osimertinib x 3yrs (+/- prior adj chemo)
@DrRoyHerbstYale
@NEJM
👩🏫Mini tweetorial 1👨🏫
✨Phase III Trial ADAURA Trial✨
🔑Key Inclusion Criteria
➡️EGFR Exon 19 del OR L878R mut
➡️ R0 resected Stage IB-IIIA (AJCC 7 ed)
💊Tx: Adjuvant Osimertinib x 3yrs (+/- prior adj chemo)
@DrRoyHerbstYale
@NEJM
📍Early/Locally Advanced NSCLC
✔️ Adjuvant osimertinib cuts recurrence risk by 73% (ADAURA).
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
✔️ Adjuvant osimertinib cuts recurrence risk by 73% (ADAURA).
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
March 20, 2025 at 7:31 PM
📍Early/Locally Advanced NSCLC
✔️ Adjuvant osimertinib cuts recurrence risk by 73% (ADAURA).
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
✔️ Adjuvant osimertinib cuts recurrence risk by 73% (ADAURA).
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
9/29 #TumorBoardTuesday
💊Pt tx w 4 cycles postop chemo then osi
👉So far NED @ 2.5 years
🙋♀️🙋But how long to continue adjuvant TKI?
🤨Varying durations studied..
3⃣ yr 👉ADAURA
2⃣ yr 👉 ALINA
♾ Indefinite 👉LAURA
🤷♀️🤷Optimal duration of adjuvant TKI is unknown..
💊Pt tx w 4 cycles postop chemo then osi
👉So far NED @ 2.5 years
🙋♀️🙋But how long to continue adjuvant TKI?
🤨Varying durations studied..
3⃣ yr 👉ADAURA
2⃣ yr 👉 ALINA
♾ Indefinite 👉LAURA
🤷♀️🤷Optimal duration of adjuvant TKI is unknown..
December 11, 2024 at 1:25 AM
9/29 #TumorBoardTuesday
💊Pt tx w 4 cycles postop chemo then osi
👉So far NED @ 2.5 years
🙋♀️🙋But how long to continue adjuvant TKI?
🤨Varying durations studied..
3⃣ yr 👉ADAURA
2⃣ yr 👉 ALINA
♾ Indefinite 👉LAURA
🤷♀️🤷Optimal duration of adjuvant TKI is unknown..
💊Pt tx w 4 cycles postop chemo then osi
👉So far NED @ 2.5 years
🙋♀️🙋But how long to continue adjuvant TKI?
🤨Varying durations studied..
3⃣ yr 👉ADAURA
2⃣ yr 👉 ALINA
♾ Indefinite 👉LAURA
🤷♀️🤷Optimal duration of adjuvant TKI is unknown..
Over the ditch we are lucky enough to have CM816, Imp010 for PDL1>50 and ADAURA available on PBS, but missing a few key proven therapies.
December 21, 2024 at 11:39 AM
Over the ditch we are lucky enough to have CM816, Imp010 for PDL1>50 and ADAURA available on PBS, but missing a few key proven therapies.
🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
March 22, 2025 at 5:28 PM
🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
I risultati sono stati presentati durante il simposio presidenziale alla World Conference on Lung Cancer Iaslc 2026
Cancro polmone Egfr-mutato, studio fase 3 Adaura: "Il 79% dei pazienti vivo a 8 anni con Osimertinib"
ebx.sh
September 17, 2026 at 4:42 AM
I risultati sono stati presentati durante il simposio presidenziale alla World Conference on Lung Cancer Iaslc 2026
Adjuvant Osimertinib in EGFR-Mutated #lungcancer: The Survival Curves Reveal the Next Set of Questions on How to Optimise Benefits #LCSM dailynews.ascopubs.org/do/adjuvant-...
Adjuvant Osimertinib in EGFR-Mutated NSCLC: The Survival Curves Reveal the Next Set of Questions on How to Optimize Benefits
Osimertinib has significantly improved outcomes for patients with <i>EGFR</i>-mutated non–small cell lung cancer in the adjuvant setting, as demonstrated by the landmark trials ADAURA and LAURA. Howev...
dailynews.ascopubs.org
March 10, 2025 at 11:39 AM
Adjuvant Osimertinib in EGFR-Mutated #lungcancer: The Survival Curves Reveal the Next Set of Questions on How to Optimise Benefits #LCSM dailynews.ascopubs.org/do/adjuvant-...
Heme/onc fellows starting July,
you already in love with thoracic oncology? ➡️ save this.
A free reference platform:
• Trials (LAURA, ADAURA, AEGEAN, KEYNOTE-189, MARIPOSA +)
• Board prep notes
• Heme/onc flashcards
• Staging flashcards (incl. lung TNM 9th ed)
🔗 HemeOncBuddy.org
you already in love with thoracic oncology? ➡️ save this.
A free reference platform:
• Trials (LAURA, ADAURA, AEGEAN, KEYNOTE-189, MARIPOSA +)
• Board prep notes
• Heme/onc flashcards
• Staging flashcards (incl. lung TNM 9th ed)
🔗 HemeOncBuddy.org
HemeOncBuddy
Heme/Onc education hub for fellows. 1,500+ pivotal trial summaries, close to 2,000 board-prep flashcards, and 120+ disease-site notes — free, searchable, no login.
hemeoncbuddy.org
May 18, 2026 at 1:00 PM
Heme/onc fellows starting July,
you already in love with thoracic oncology? ➡️ save this.
A free reference platform:
• Trials (LAURA, ADAURA, AEGEAN, KEYNOTE-189, MARIPOSA +)
• Board prep notes
• Heme/onc flashcards
• Staging flashcards (incl. lung TNM 9th ed)
🔗 HemeOncBuddy.org
you already in love with thoracic oncology? ➡️ save this.
A free reference platform:
• Trials (LAURA, ADAURA, AEGEAN, KEYNOTE-189, MARIPOSA +)
• Board prep notes
• Heme/onc flashcards
• Staging flashcards (incl. lung TNM 9th ed)
🔗 HemeOncBuddy.org
Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research
https://cancerletter.com/funding-opportunities/20260925_8a/
https://cancerletter.com/funding-opportunities/20260925_8a/
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared
cancerletter.com
September 28, 2026 at 10:00 PM
Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research
https://cancerletter.com/funding-opportunities/20260925_8a/
https://cancerletter.com/funding-opportunities/20260925_8a/
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds
https://cancerletter.com/clinical-roundup/20260925_9a/
https://cancerletter.com/clinical-roundup/20260925_9a/
FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter
FDA granted approval for Lyrfigtu (lirafugratinib) as a treatment option for patients with cholangiocarcinoma with FGFR2
cancerletter.com
September 28, 2026 at 12:00 PM
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds
https://cancerletter.com/clinical-roundup/20260925_9a/
https://cancerletter.com/clinical-roundup/20260925_9a/
Plasma MRD kinetics in the 18 of 220 ADAURA patients who had baseline MRD+ after surgery +/- chemotherapy.
Any reason why the baseline prevalence of MRD+ is higher in the placebo group? Groups were well matched for chemo receipt, nodal staging, surgery type. Just small n? #OncSky
Any reason why the baseline prevalence of MRD+ is higher in the placebo group? Groups were well matched for chemo receipt, nodal staging, surgery type. Just small n? #OncSky
March 19, 2025 at 3:03 AM
Plasma MRD kinetics in the 18 of 220 ADAURA patients who had baseline MRD+ after surgery +/- chemotherapy.
Any reason why the baseline prevalence of MRD+ is higher in the placebo group? Groups were well matched for chemo receipt, nodal staging, surgery type. Just small n? #OncSky
Any reason why the baseline prevalence of MRD+ is higher in the placebo group? Groups were well matched for chemo receipt, nodal staging, surgery type. Just small n? #OncSky
La Dra. Estelamari Rodriguez analiza el potencial de trasladar la terapia dirigida a una etapa más temprana del NSCLC.
Mira el video completo aquí: www.youtube.com/watch?v=bNc3...
#TerapiaDirigida #CáncerDePulmón #Estadíatemprana #Quimioterapia #Radiación #Mutaciónegfr #Adaura
Mira el video completo aquí: www.youtube.com/watch?v=bNc3...
#TerapiaDirigida #CáncerDePulmón #Estadíatemprana #Quimioterapia #Radiación #Mutaciónegfr #Adaura
Uso de Terapia Dirigida en Enfermedades en Etapas más Tempranas - Cáncer de Pulmón 2023
Destacados oncólogos se reúnen en este evento grabado en vivo para debatir las opciones de terapia dirigida para pacientes con cáncer de pulmón. Incluye una ...
www.youtube.com
January 18, 2024 at 5:12 PM
La Dra. Estelamari Rodriguez analiza el potencial de trasladar la terapia dirigida a una etapa más temprana del NSCLC.
Mira el video completo aquí: www.youtube.com/watch?v=bNc3...
#TerapiaDirigida #CáncerDePulmón #Estadíatemprana #Quimioterapia #Radiación #Mutaciónegfr #Adaura
Mira el video completo aquí: www.youtube.com/watch?v=bNc3...
#TerapiaDirigida #CáncerDePulmón #Estadíatemprana #Quimioterapia #Radiación #Mutaciónegfr #Adaura
早期EGFR変異肺がんのタグリッソ術後療法、8年生存データをAstraZenecaが発表──ADAURA試験の長期追跡結果を整理
stellanews.life/technology/1... #ADAURA #8年生存
stellanews.life/technology/1... #ADAURA #8年生存
早期EGFR変異肺がんのタグリッソ術後療法、8年生存データをAstraZenecaが発表──ADAURA試験の長期追跡結果を整理
AstraZenecaは2026年9月14日、EGFR変異陽性の早期非小細胞肺がんを対象としたADAURA第3相試験について、術後補助療法としてのタグリッソ（オシメルチニブ）の8年時点における全生存期間データを発表した。主要な結果と安全性、臨床的含意を整理する。
stellanews.life
September 16, 2026 at 10:30 PM
早期EGFR変異肺がんのタグリッソ術後療法、8年生存データをAstraZenecaが発表──ADAURA試験の長期追跡結果を整理
stellanews.life/technology/1... #ADAURA #8年生存
stellanews.life/technology/1... #ADAURA #8年生存